INCY Incyte Corporation

$102.06

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Incyte Corporation

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.

Website: https://www.incyte.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
879169
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, US
Valuation
Market Cap
$11.27B
P/E Ratio
388.07
PEG Ratio
0.37
Price to Book
3.27
Performance
EPS
$0.15
Dividend Yield
—
Profit Margin
0.77%
ROE
0.75%
Technicals
50D MA
$65.63
200D MA
$67.66
52W High
$83.95
52W Low
$50.35
Fundamentals
Shares Outstanding
194M
Target Price
$73.40
Beta
0.90

INCY EPS Estimates vs Actual

● Estimated
● Actual

INCY News & Sentiment

Nov 20, 2025 • Zacks Commentary BULLISH
Why Incyte ( INCY ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nov 19, 2025 • Zacks Commentary BULLISH
Why Incyte ( INCY ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Nov 13, 2025 • Motley Fool SOMEWHAT-BULLISH
Cellebrite ( CLBT ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, November 12, 2025 at 5:00 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
Nov 12, 2025 • Benzinga SOMEWHAT-BULLISH
Peering Into Incyte Corp's Recent Short Interest - Incyte ( NASDAQ:INCY )
Incyte Corp's ( NYSE:INCY ) short interest as a percent of float has risen 10.08% since its last report. According to exchange reported data, there are now 9.36 million shares sold short, which is 6.77% of all regular shares that are available for trading.
Nov 12, 2025 • GlobeNewswire NEUTRAL
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of ...
Nov 06, 2025 • GlobeNewswire NEUTRAL
Knight Therapeutics Reports Third Quarter 2025 Results
Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance ...
Sentiment Snapshot

Average Sentiment Score:

0.285
50 articles with scored sentiment

Overall Sentiment:

Bullish

INCY Reported Earnings

Jul 29, 2025
Jun 30, 2025 (Pre market)
0.1 Surprise
  • Reported EPS: $1.57
  • Estimate: $1.47
  • Whisper: —
  • Surprise %: 6.8%
Apr 29, 2025
Mar 31, 2025 (Pre market)
0.04 Surprise
  • Reported EPS: $0.80
  • Estimate: $0.76
  • Whisper: —
  • Surprise %: 5.3%
Feb 10, 2025
Dec 31, 2024 (Pre market)
-0.12 Surprise
  • Reported EPS: $1.43
  • Estimate: $1.55
  • Whisper: —
  • Surprise %: -7.7%
Oct 29, 2024
Sep 30, 2024 (Pre market)
-0.25 Surprise
  • Reported EPS: $0.54
  • Estimate: $0.79
  • Whisper: —
  • Surprise %: -31.6%
Jul 30, 2024
Jun 30, 2024 (Pre market)
-0.27 Surprise
  • Reported EPS: $-1.82
  • Estimate: $-1.55
  • Whisper: —
  • Surprise %: -17.4%
Apr 30, 2024
Mar 31, 2024 (Pre market)
-0.2 Surprise
  • Reported EPS: $0.64
  • Estimate: $0.84
  • Whisper: —
  • Surprise %: -23.8%
Feb 13, 2024
Dec 31, 2023 (Pre market)
-0.1 Surprise
  • Reported EPS: $1.06
  • Estimate: $1.16
  • Whisper: —
  • Surprise %: -8.6%
Oct 31, 2023
Sep 30, 2023 (Pre market)
0.08 Surprise
  • Reported EPS: $1.10
  • Estimate: $1.02
  • Whisper: —
  • Surprise %: 7.8%
Aug 01, 2023
Jun 30, 2023 (Pre market)
0.16 Surprise
  • Reported EPS: $0.99
  • Estimate: $0.83
  • Whisper: —
  • Surprise %: 19.3%

Financials